Clinical trials
GIST clinical trials
Below are recruiting gist clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05009927RecruitingPhase 2
Check whether continuing imatinib works after long GIST control
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
BesançonAges 18 years+ - NCT07697248Recruiting
GIST patient registry study
This study is creating a registry to track people with GIST over time. Participating helps researchers learn more about the disease and improve future care.
Wayne, New JerseyAges Any age - NCT07406633RecruitingPhase 2
KQB198 plus imatinib for advanced GIST
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05152472RecruitingPhase 2
Imatinib plus atezolizumab versus imatinib alone for advanced GIST
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Lyon, RhôneAges 18 years+ - NCT07581977Recruiting
A Clip Tool for Removing Small Stomach Growths
This trial tests a new two-tooth clip device designed to help doctors safely remove small gastrointestinal tumors (GISTs) from the stomach using endoscopy—a thin camera inserted through the mouth. The clip may make the removal procedure easier and safer.
BeijingAges 18–85 - NCT07522762Recruiting
Long-term life after advanced GIST on targeted drug therapy
This study follows people who have been taking targeted cancer drugs (called TKIs) for advanced GIST for at least 2 years to understand how these long-term treatments affect quality of life, side effects, and daily living. Researchers want to learn what challenges patients face and how to better support them.
Amsterdam, North HollandAges 18 years+ - NCT07411118Recruiting
Comparing two ways to remove stomach GIST tumors with an endoscope
This trial compares two endoscopic techniques (EFTR and STER) for removing small to medium-sized GIST tumors from the stomach wall. It aims to see which method is safer and more effective.
ShanghaiAges 18–75 - NCT07405125Recruiting
Robotic surgery for stomach tumors in tricky spots
This trial tests the safety of using a robot to remove small stomach tumors (GISTs) that are in hard-to-reach places. It aims to see if robotic surgery is a good option for you.
Nanjing, JiangsuAges 18–75 - NCT07379047RecruitingPhase 2/Phase 3
Testing NB003 for advanced GIST after prior treatments
This trial tests a new drug called NB003 for people with advanced GIST (a type of stomach or intestinal tumor) that has stopped responding to or could not be tolerated after standard treatments like imatinib or sunitinib. The goal is to see if NB003 can help shrink or control the tumor.
Hefei, AnhuiAges 18 years+ - NCT07096609RecruitingPhase 1/Phase 2
Lenvatinib for GIST after imatinib, sunitinib, and regorafenib
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
SeoulAges 20 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Birmingham, AlabamaAges 18 years+ - NCT06640361RecruitingPhase 3
Study of olverembatinib for a rare type of GIST
This trial tests a new drug, olverembatinib, for GIST that lacks the SDH enzyme and has gotten worse after at least one prior treatment. It aims to see if the drug can stop or shrink the tumor.
Guangzhou, GuangdongAges 12 years+ - NCT06630234RecruitingPhase 1/Phase 2
Testing a new drug for advanced GIST with specific gene changes
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
Scottsdate, ArizonaAges 18 years+ - NCT04557969Recruiting
Surgery and tumor testing in gastrointestinal stromal tumors (GIST)
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
Bethesda, MarylandAges 6 years+ - NCT03594422RecruitingPhase 1
Testing an oral drug for GIST or other solid tumors
This Phase 1 trial tests HQP1351, a new oral cancer drug, in people with advanced GIST or other solid tumors that have not responded to prior treatment. It’s mainly designed to check safety and how the drug works in the body, which may lead to better options for tumors that have progressed.
Guangzhou, GuangdongAges 12 years+ - NCT05408897Recruiting
Blood test to predict risk after surgery for high-risk GIST
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
Beijing, Beijing MunicipalityAges Any age - NCT05751733Recruiting
Apatinib versus standard drug for advanced GIST after imatinib
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
Changsha, HunanAges 18 years+ - NCT07825571Recruiting
Gender inclusive sexuality talks program
This study tests a program that helps transgender, gender diverse, or lesbian or bisexual female youth (ages 12-18) and their parents have supportive conversations about sexuality and gender.
Philadelphia, PennsylvaniaAges 12–100 - NCT06507683Recruiting
Radiation plus ripretinib for advanced GIST
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07689201RecruitingPhase 2
Studying a new targeted drug for advanced GIST after other treatments fail
This study tests a new pill called velzatinib for people with GIST that has spread or can't be removed by surgery, after other treatments have stopped working. It may help shrink the tumor or slow its growth.
FukuokaAges 18 years+ - NCT07673861Recruiting
Using ctDNA to find resistance and guide cancer treatment
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
LondonAges 18 years+ - NCT07618377RecruitingPhase 1
New Drug for Gastrointestinal Tumors After Multiple Treatments
This study tests a new drug called DCC-2618 for patients with GIST (a rare stomach/intestinal cancer) who have already tried at least three other treatments. The goal is to see if this drug can slow or shrink tumors in patients whose cancer has stopped responding to standard medications.
Kashiwa, ChibaAges 18 years+ - NCT07559864RecruitingPhase 2
Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07550582Enrolling by invitationPhase 2
Surgery for small tumors at the food pipe opening
This trial tests a new surgical approach combining laparoscopic (minimally invasive) surgery with endoscopy (a camera procedure) to remove small tumors located where the esophagus meets the stomach. The goal is to safely remove these tumors while preserving normal function.
Beijing, Beijing MunicipalityAges 18–80
Hear when a new GIST trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
GIST trials by city
Studies with a site in or near these metro areas.
Common questions
- Are there clinical trials for gist?
- Yes. Clin2 currently lists 45 recruiting gist studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gist trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gist trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.